Literature DB >> 2306737

Increased local antitumor effects of interleukin 2 liposomes in mice with MCA-106 sarcoma pulmonary metastases.

P M Anderson1, E Katsanis, A S Leonard, D Schow, C M Loeffler, M B Goldstein, A C Ochoa.   

Abstract

The effects of liposome formulations of interleukin 2 (IL-2) and local route were studied in C57BL/6 mice with MCA-106 sarcoma pulmonary metastases. IL-2 liposomes made by hydration of powdered dimyristoyl-phosphatidylcholine with aqueous recombinant IL-2 had 95% of the IL-2 associated with the lipid fraction. When mice with pulmonary micrometastases were treated once daily with free cytokine on days 5, 6, and 7 after tumor inoculation, the intrathoracic route was superior to the i.p. or s.c. routes. When IL-2 liposomes were administered by the local intrathoracic route, significantly better antitumor effects (P less than 0.01) were seen compared to empty liposomes or free IL-2 as determined by (a) increased survival and (b) reduced numbers of pulmonary metastases. Minimal toxicity was observed. Results indicate that local route and incorporation of IL-2 in liposomes may enhance therapeutic efficacy and facilitate more practical daily dosing regimens.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2306737

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  An orthotopic model of murine osteosarcoma with clonally related variants differing in pulmonary metastatic potential.

Authors:  C Khanna; J Prehn; C Yeung; J Caylor; M Tsokos; L Helman
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

2.  Hepatic immunopotentiation by galactose-entrapped liposomal IL-2 compound in the treatment of liver metastases.

Authors:  K Okuno; K Nakamura; A Tanaka; K Yachi; M Yasutomi
Journal:  Surg Today       Date:  1998       Impact factor: 2.549

Review 3.  Particle-mediated delivery of cytokines for immunotherapy.

Authors:  David A Christian; Christopher A Hunter
Journal:  Immunotherapy       Date:  2012-04       Impact factor: 4.196

4.  Interleukin-2-containing liposomes: interaction of interleukin-2 with liposomal bilayers and preliminary studies on application in cancer vaccines.

Authors:  J J Bergers; W Den Otter; H F Dullens; C T Kerkvliet; D J Crommelin
Journal:  Pharm Res       Date:  1993-12       Impact factor: 4.200

Review 5.  Nanoparticle-Based Manipulation of Antigen-Presenting Cells for Cancer Immunotherapy.

Authors:  Ronnie H Fang; Ashley V Kroll; Liangfang Zhang
Journal:  Small       Date:  2015-09-02       Impact factor: 13.281

Review 6.  Liposomes as carriers of cancer chemotherapy. Current status and future prospects.

Authors:  S Kim
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

Review 7.  Interleukin-2 in cancer treatment: disappointing or (still) promising? A review.

Authors:  R A Maas; H F Dullens; W Den Otter
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

Review 8.  Effects of route and formulation on clinical pharmacokinetics of interleukin-2.

Authors:  P M Anderson; M A Sorenson
Journal:  Clin Pharmacokinet       Date:  1994-07       Impact factor: 6.447

9.  Local therapy of cancer with free IL-2.

Authors:  Willem Den Otter; John J L Jacobs; Jan J Battermann; Gerrit Jan Hordijk; Zachary Krastev; Ekaterina V Moiseeva; Rachel J E Stewart; Paul G P M Ziekman; Jan Willem Koten
Journal:  Cancer Immunol Immunother       Date:  2008-07       Impact factor: 6.968

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.